Last reviewed · How we verify
Botulinum Toxin Type A 900kDa
Botulinum toxin type A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.
Botulinum toxin type A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis. Used for Cervical dystonia, Blepharospasm, Strabismus.
At a glance
| Generic name | Botulinum Toxin Type A 900kDa |
|---|---|
| Also known as | BOTOX® |
| Sponsor | Allergan |
| Drug class | Neurotoxin; acetylcholine release inhibitor |
| Target | SNAP-25 (synaptosome-associated protein of 25 kDa) |
| Modality | Biologic |
| Therapeutic area | Neurology; Aesthetics; Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
The toxin is a zinc-dependent endopeptidase that cleaves SNAP-25 (synaptosome-associated protein of 25 kDa), preventing acetylcholine vesicles from fusing with the presynaptic membrane. This results in flaccid paralysis of the injected muscle that typically lasts 3–4 months. The 900 kDa form includes associated proteins that stabilize the toxin complex.
Approved indications
- Cervical dystonia
- Blepharospasm
- Strabismus
- Chronic migraine
- Severe primary axillary hyperhidrosis
- Glabellar lines (cosmetic)
- Crow's feet (cosmetic)
- Forehead lines (cosmetic)
Common side effects
- Headache
- Neck pain
- Injection site pain or bruising
- Muscle weakness (localized)
- Ptosis (eyelid drooping)
- Diplopia (double vision)
- Flu-like symptoms
Key clinical trials
- Extension Study of ABP-19000 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 in Cervical Dystonia (PHASE2)
- A Phase 2 Study to Evaluate the Safety and Efficacy of ABP-450 in the Treatment of Cervical Dystonia (PHASE2)
- Comparison of Two Botulinum Type A Products in the Treatment of Blepharospasm (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |